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A BSTRACT
Breast cancer accounts for 20% of all female cancers. Many risk factors have been 
identified but a positive family history remains one of the most important risk fac-
tors, with first-degree relatives of patients having a 2-fold elevated risk. Known breast 
cancer susceptibility genes such as brca1 and brca2 explain only 20-25% of this 
risk, suggesting the existence of other breast cancer susceptibility genes.
Here we report the results of a genome-wide linkage scan in 55 high-risk Dutch 
breast cancer families with no mutations in brca1 and brca2. In addition we per-
formed cgh-analyses in 61 tumors of these families and 31 sporadic tumors. 
Twenty-two of these cancer families were also included in the previous linkage study 
by the Breast Cancer Linkage Consortium.1 Three regions were identified with para-
metric hlod scores >1, and three with non-parametric lod scores >1.5. Upon 
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further marker genotyping for the candidate loci, and the addition of another 30 
families to the analysis, only the locus on chromosome 9 (9q21-22, marker D9S167) 
remained significant, with a non-parametric multipoint lod score of 3.96 (parame-
tric hlod 0.56, α=0.18). With cgh-analyses we observed preferential copynumber 
loss at BAC RP11-276H19, containing D9S167 in familial tumors as compared to 
sporadic tumors (p<0.001). Five candidate genes were selected from the region 
around D9S167 and their coding regions subjected to direct sequence analysis in 16 
probands. No clear pathogenic mutations were found in any of these genes. 
INTRODUCTION
Breast cancer is the most commonly occurring cancer among women, accounting 
for 22% of all female cancers and the cumulative lifetime risk for a woman to develop 
breast cancer is approximately 1 in 10.2 Many risk factors have been identified but a 
positive family history remains among the most important ones established for 
breast cancer, with first-degree relatives of patients having an approximately 2-fold 
elevated risk.3 This risk increases with the number of affected relatives and is greater 
for women with relatives affected at a young age, bilateral disease or a history of be-
nign breast disease.4,5 It is currently estimated that approximately 20-25% of this risk 
is explained by known breast cancer susceptibility genes, mostly those conferring 
high risks, such as brca1 and brca2.6 This suggests that other susceptibility genes 
remain to be found, although it is not entirely clear which genetic model explains the 
remainder of familial risk best.7-9 Depending on the population investigated, some of 
the risk could still be due to rare, moderately penetrant autosomal dominant effects, 
a common recessive effect, or a polygenic model. Recently the Breast Cancer Link-
age Consortium (bclc) published the results of a genome-wide linkage search for 
new breast cancer susceptibility genes in 149 high risk breast cancer families.1 The 
highest lod score obtained was 1.80 under the dominant model, for a region on 
chromosome 4. A maximum heterogeneity-lod (hlod) score of 2.40 was found on 
chromosome arm 2p in a subset of families with four or more cases of breast cancer 
diagnosed below age 50 years.1 Other studies scanning for linkage were also unable 
to detect significant lod scores, but were much smaller in terms of number of fami-
lies included.10,11
The failure to detect strong linkage signals might reflect extensive locus heterogen-
eity, whereby multiple susceptibility loci each explain only a small proportion of fa-
milies. Greater statistical linkage power might be achieved by considering subsets of 
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families from more homogeneous populations in which the number of such loci 
might be reduced. We have here performed a search for linkage in a set of 55 breast 
cancer families of Dutch origin that are unlikely to be segregating brca1 or brca2 
mutations. The cumulative lifetime risk of developing breast cancer in the Nether-
lands is about 1 in 9 women, which ranks among the highest worldwide. Founder 
effects at several major breast cancer loci have been detected in the Dutch popula-
tion,12-14 as well as for many other disease genes. The assumption of reduced genetic 
heterogeneity for breast cancer susceptibility in the Netherlands is therefore not un-
realistic. No significant lod scores were obtained in parametric analyses under a do-
minant or recessive model. Non-parametric (allele-sharing) analysis identified a lo-
cus on chromosome 9q21 with a multipoint npl-score of 3.96 (marker D9S167), but 
no clearly pathogenic mutations were detected in 5 candidate genes flanking this 
marker in 16 probands from families putatively linked to chromosome 9.
MATERIALS AND METHODS
Family collection
The families were ascertained through the Clinical Genetic Centers in Leiden, Rot-
terdam, and Nijmegen, as well as through the Netherlands Foundation for the De-
tection of Hereditary Tumors (stoet). The families were eligible for inclusion if 
there were at least three cases diagnosed with breast cancer before the age of 60, no 
cases of ovarian cancer, and no cases of male breast cancer.1 Polymorphic marker 
information had to be retrievable for at least three cases under 60, either by direct 
genotyping of blood samples, or by inferring from genotyped spouses and children. 
The resulting 55 families constituted our ‘linkage search group’ (208 genotyped 
breast cancer cases). Twenty-two of these families were also included in the genome-
wide linkage search conducted by the bclc.1 Another 30 families (119 breast cancer 
cases), were designated ‘linkage conformation group’, because they were selected on 
the same cancer phenotype, but differed slightly from the search group in that they 
did not meet the genotype or age of onset criteria. Thus, there were 4 families with 
two genotyped cases diagnosed before the age 60, and one diagnosed at the age 60, 
18 families with three or more cases under 60, of which only two were genotyped, 
3 families with three or more cases under 60, of which only one was genotyped, and 
5 families with two genotyped cases diagnosed before 60, one of whom is a bilateral 
case (with both primaries diagnosed before age 60). To meet the ‘three cases’ sam-
pling criteria in these families, we also genotyped cases diagnosed above 60 if they 
had donated a blood sample (67 breast cancer cases). 
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Paraffin-embedded tumor samples and pathological reports or medical reports were 
retrieved where available. Blood samples were collected after obtaining written in-
formed consent. The institutional ethical committees of all of the hospitals involved 
approved this study. 
brca1 and brca2 mutation testing
In each family, the youngest breast cancer patient from whom a blood sample was 
available was tested for mutations in the brca1 and brca2 genes (and for many fa-
milies the next youngest as well). The joint Clinical Genetic Centers applied a vari-
ety of methodologies. The largest central exons (exon 11 in brca1 and brca2, exon 
10 of brca2) were scanned by protein truncation tests.15 The small exons were 
scanned for mutations by denaturating gradient gel electrophoreses (dgge) or direct 
sequencing. All of the laboratories specifically assayed the presence of large founder 
deletions in brca1 by deletion junction-pcr.13 The entire coding sequences of brca1 
and brca2 were investigated by conformation-sensitive gel electrophoresis (csge) in 
families that were incompletely scanned at the time of ascertainment.16 Since 2002, 
each center offers full sequence analysis and dgge covering the entire coding regi-
ons of both genes, and Multiple Ligation-dependent Probe Amplification (mlpa) to 
detect large deletions/duplications in brca1.17
Linkage analysis
For the genome-wide linkage search, the Applied Biosystems Linkage Mapping Set 
MD10, consisting of 416 microsatellite markers at ~10 cM average spacing, was ana-
lyzed on an abi3700 dna sequencer.1 Additional markers were used to investigate 
the region of interest on chromosome 9. Genotypes were called automatically using 
Genemapper software and were then checked manually by two individuals. dna 
from ceph 1347-02 was typed as reference to ensure consistency of allele sizing. Al-
lele frequencies for parametric linkage analyses were calculated based on one rand-
omly chosen individual from each family. Multipoint linkage analyses were carried 
out using the program genehunter version 2.1-b.18 We used a model in which sus-
ceptibility to breast cancer is conferred by a dominant allele with a reduced pene-
trance and a population frequency of 0.003.19,20 The risk of breast cancer by age 80 
was assumed to be 0.85 in carriers and 0.096 in non-carriers. Risks are modeled in 
seven age categories (<30, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+) as descri-
bed.20 Under the recessive model, the risk to carriers and noncarriers were identical 
to those under the dominant model, but the disease allele frequency was assumed to 
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be 0.08. We used the multipoint lod-scores for each family to compute heterogeneity 
lod scores, using the standard admixture model, and hence estimated the propor-
tion of families (α) linked to the putative ‘brcax’ locus by maximizing the hetero-
geneity lod score.  Non-parametric linkage analyses were carried out by the pro-
gram genehunter version 2.1-b and merlin version 0.9.12b.21 Both the singlepoint 
and multipoint settings were used, as well as both the ‘pairs’ and ‘all’ setting.
snp-genotyping
Four single nucleotide polymorphisms were initially selected from an approximately 
65-kb region surrounding D9S167. More recently, however, these snp’s were re-
 positioned 1.74 Mb distal of this marker by the human genome sequencing effort. 
We then selected 4 other snp’s, immediately adjacent to D9S167 and covering about 
17 kb within the 48-kb linkage disequilibrium-block around marker D9S167 (www.
hapmap.org). These were rs12335588 (hapmap position 82,996,423), rs10867942 
(83,002,124), rs11139937 (83,011,568), and rs11139938 (83,011,664). Marker 
D9S167 is at hapmap position 83,013,562. Primers were designed in such a way that 
the polymorphism would create or destroy a restriction site.22 pcr-products were 
digested by the appropriate restriction enzyme, and analysed on a 2.5% agarose gel. 
Results were scored by two observers independently. Data from all 8 snp’s were used 
to reconstruct haplotypes around D9S167.
Chromosome 9 copy number analysis
We performed array-cgh-analysis of 61 paraffin-embedded tumor samples from 58 
patients from 27 families, using a method described previously.23,24 Similar material 
from 31 sporadic cases served as control. These arrays contain approximately 3,500 
bac clones, of which 13 derive from an 8-cM region of interest on chromosome 9. 
The bac’s were considered to report copy number gain if the ratio of tumor derived 
genomic dna compared to normal dna exceeded 0.2 on a 2log-scale, and copy num-
ber loss if the signal was below −0.2. The full dataset describing gains and losses on 
all chromosomes in this patient material will be described elsewhere (Van Beers et 
al., manuscript in preparation).
Sequence analysis of candidate genes
All known genes in an 14-cM interval D9S175-D9S167-D9S283 were retrieved from 
Ensemble (release 42). The cellular functions of these genes – in as much as they 
were known – were retrieved from omim. A literature search was then performed by 
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a computer-program dubbed ‘Anni’, which can find functional associations between 
large numbers of genes and other biomedical concepts (in this case ‘breast cancer’) 
from free-text literature.25 For each gene, a profile of related concepts was construc-
ted that summarizes the context in which the gene is mentioned in literature. In 
addition, all genes from the region were analyzed by software termed ‘Prioritizer’.26 
On this basis, 5 genes (of the 14 annotated genes with a known function in an approx 
5-cM region around D9S167) were selected for direct sequence analysis in a set of 16 
dna samples from breast cancer patients from 16 different families. These families 
were selected because analysis of genotype data with the program ‘Haploview’27 had 
indicated that all patients share a haplotype in this region. Candidate genes were 
analyzed by dna sequence analysis on the abi3730 Prism Genetic Analyzer (Applied 
Biosystems, Foster City, CA)and the Mutation Surveyor® software package.
TABLE 1
Maximum LOD scores in 55 breast cancer families by chromosome under the 
dominant, nonparametric and recessive model.
Chromosome Position Model HLOD or  Alpha
   NPL LOD score 
1 226 Dominant 1.40 0.12
4 64 NPL 1.26 
6 164 NPL 1.94 
6 164 Recessive 1.52 0.53
7 90 NPL 1.25 
9 30 NPL 2.22 
9 86 NPL 2.34 
9 88 Recessive 1.18 0.47
9 90 Dominant 1.24 0.43
15 114 Dominant 1.19 0.29
15 114 NPL 1.12 
21 22 NPL 1.72 
Generated with the Genehunter software package. Position (cM) based on deCode map.  
HLOD, heterogeneity LOD score (dominant and recessive models);  
NPL, nonparametic (allele sharing) LOD score.  
Alpha is the proportion of linked families in the admixture model.
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RESULTS
Genome-wide linkage scan
We performed a genome-wide linkage analysis with 416 microsatellite markers, with 
an average spacing of approximately 10 cM in the group of 55 linkage search fami-
lies. The highest heterogeneity lod-score generated by genehunter under a para-
metric dominant model was 1.40 on chromosome 1 at position 226 cM (Table 1, 
Figure 1). Two other regions with hlod-scores greater than 1.0 were identified on 
chromosome 9 (hlod=1.23 at position 90 cM) and 15 (hlod=1.19 at position 114 
cM). Under a recessive model hlod-scores >1.0 were found on chromosome 6 (164 
cM) and 9 (88 cM). With non-parametric linkage analysis (npl) we identified seven 
regions with a NPL-score higher than 1 (chromosome 4, 6, 7, 9, 15 and 21). The hi-
ghest npl-score found was on chromosome 9 (npl=2.34, 86 cM, p=0.015). A se-
cond, distinct region on chromosome 9 had an npl-score of 2.23 (30 cM, p=0.019). 
This second region also showed a hlod-score >1 under the dominant model. To 
TABLE 2
Haplotypes around D9S167
 All families Complete sharing Near complete sharing3
D9S167 Number of  Number of Number of Number of Number of Number of Total nr. of
allele (bp) families1 haplotypes2 families haplotypes families haplotypes haplotypes4
313 11 7 2 1 2 2 2
317 25 19 3 2 3 3 4
319 20 11 2 2 1 1 3
321 29 22 6 6 2 2 7
323 9 8 2 1 0 0 1
325 15 12 3 2 0 0 2
327 5 7 1 1 1 1 1
329 2 2 0 0 1 1 1
331 9 9 1 1 0 0 1
333 3 3 0 0 1 1 1
335 13 14 4 4 1 1 5
337 3 3 1 1 0 0 1
Totals   25 21 12 12 29
       
1 Total number of families (sharing and non-sharing)
2 Total number of different haplotypes in the complete set of families
3 Families with  > 80% sharing, excluding families with complete sharing
4 Total number of different haplotypes in families with > 80% sharing
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evaluate these linkage signals further we genotyped an additional 30 families (con-
firmation group) for the microsatellite markers on chromosome 1, 6, 9, 15, and 21 at 
which the peak lod scores were observed. For all these loci the evidence for linkage 
decreased, except for the locus on chromosome 1, for which the hlod increased to 
1.46 (α=0.13, p=0.39). The locus at position 86 cM on chromosome 9 decreased only 
slightly (npl= 1.98, p=0.028) and the hlod was 0.56 (α=0.18). 
We then also generated lod-scores using the method of Kong and Cox with the 
merlin software package, because this method is less conservative when marker 
information is not complete (Figure 1). The multipoint lod-score at position 86 cM 
on chromosome 9 was 3.06 (p=9x10_5) at marker D9S167 in the 55 families, and 
increased to 3.96 (p=10_5) when the other 30 families were added to the analysis. The 
single-point lod-score over all 85 families for D9S167 was 4.63 (p=10_6). To evalu-
ate this region on chromosome 9 further we genotyped 4 additional microsatellite 
markers, i.e., D9S1843 and D9S1674 proximal of D9S167, and D9S1865 and 
D9S1812 distal of it, defining a 9.4 cM-region. With these additional markers the 
multipoint lod-score calculated by merlin at D9S167 in the 85 families declined to 
3.02, while those at D9S1843 and D9S287 were below 1.5 (Figure 2). This defined the 
linked region to be between the markers D9S1674 and D9S287 (~15.7 cM).
Haplotype analysis
To aid haplotyping around D9S167, we genotyped 8 snp’s, 4 of which immediately 
proximal of D9S167 in a ~48-kb LD-block, and 4 covering a 65-kb region about 1.7 
Mb distal of D9S167. We analyzed haplotype-sharing in each family with the pro-
gram ‘Haploview’.27 In 32 families all genotyped patients shared an allele at D9S167, 
but in 5 families this allele was on a different haplotype, indicating that the shared 
alleles were not identical by descent (IBD). In another four families not all patients 
were succesfully genotyped at D9S167, but in two of those the patients shared a ha-
plotype from D9S1674 to D9S1812, suggesting allele-sharing at D9S167. Thus, in 25 
families all patients shared an allele at D9S167 IBD (Table 2), in total comprising 10 
different alleles (range: 1 – 6 families per allele) on 21 different haplotypes. In 50 
families there was no sharing of an allele among genotyped patients (in 3 families the 
marker data did not allow phasing of the haplotypes). In 12 of these 50 families, 
more than 80% of the patients shared the same haplotype (4 out of 5 patients in 5 
families, 5 out of 6 in 4 families, and 6 out of 7, 7 out of 8, 8 out of 10 in 1 family 
each). Again, 8 different D9S167-alleles were shared on a total of 12 different haplo-
types (Table 2). Overall, the 12 different D9S167-alleles found to be shared either 
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Figure 1. hlod scores by chromosome for the dominant model (blue line), as computed by genehunter, 
and nonparametric lod scores (red line), as computed by merlin, in 55 breast cancer families.
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completely or almost completely, did so on 29 different haplotypes. Although, 
 depending on the number of markers considered around D9S167, a suggestive core 
haplotype could sometimes be discerned between two or more haplotypes (data not 
shown). These results support the npl scores for D9S167, but also indicate extensive 
allelic heterogeneity for this sharing, as well as genetic heterogeneity across families 
because not all families contribute to the npl score.
Candidate gene analysis
We selected five genes from the region between markers D9S1843 and D9S283, on 
the basis of their presumed cellular function (see Materials & Methods). These inclu-
ded ubqln1, rasef, dapk1, tle1, and gadd45γ. The entire coding regions of these 
genes were sequenced in 16 patients from 16 families displaying complete haplotype 
sharing at D9S167. Nineteen variants were found in one or more patients (Table 3), 
11 of which were known snp’s. For several variants we detected homozygotes for 
both alleles, making them unlikely candidates for susceptibility alleles. Of all the 
exonic variants found, there was only one missense change, in tle1 in one family. 
This variant did not co-segregate with disease. Three of the 6 intronic variants were 
known snp’s, and none were predicted to affect the nearest splice-site. The latter was 
also found for all the neutral exonic changes. We conclude that no clear disease-re-
lated changes were detected in this screen.
cgh-analysis
Copy number changes of the linked region on chromosome 9 were investigated in 
61 tumors from 27 families by examing the intensity ratios of the 13 bac clones re-
presenting this region on the array (Table 4). We were able to compare the results of 
22 tumors from 10 families that displayed complete sharing of a 8-cM haplotype 
around D9S167 in all patients (‘linked tumors’), with 39 tumors from 17 families 
without such haplotype sharing (‘unlinked tumors’). A high proportion of linked 
tumors (55%) showed copy number loss at a BAC RP11-276H19 containing the 
gas1 gene and D9S167, and none showed gain. However, this was not statistically 
different from the unlinked tumors in which 31% showed copy loss at this bac. We 
did observe a significant difference in the percentage of brcax tumors with loss of 
this bac as compared to sporadic tumors (average 2log ratio of −0.208 as compared 
with a 2log ratio of 0.088 for control tumors). This difference has a two-tailed un-
paired t-test p-value of 0.00039. 
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TABLE 3
Gene changes detected in sequence analysis of 5 candidate genes
Gene name Gene Change Exon / Times found  Known SNP Splice-site  Co-
  intron heterozygous1  prediction2 segregation3
DAPK1 c.393C>T, p.His131His Exon 4 1 No No change NI
 TTCA(G/A)GAT,  143481A>AG,  Exon 9 1 (and 2 minor  No No change NI
 p.267Gln>Gln  homozygotes)   
 g.144573A>AG Intron 9 7 (and 3 minor  rs3118846 No change NI
   homozygotes)   
 g.150139G>AG Intron 14 4 rs2274607 No change NI
 c.1608C>T, p.Asp537Asp Exon 16 13 rs3818584 No change NI
 c.1830G>A, p.Gly610Gly Exon 18 2 No No change NI
 g.201463G>T  Intron 23 3 rs3128495 No change NI
 c.3597C>T, p.Arg1200Arg Exon 26 10 rs3118863 No change NI
TLE1 c.983C>T, p.Thr328Met Exon 12 1 No No change No
 c.1101A>G, p.Pro367Pro Exon 13 1 No No change NI
GADD45G c.102+65G>C Intron 1 4 rs3138502 No change NI
 c.157-18_19delCC;-18_19insCTAG Intron 2 2 No No change No
RASEF c.785C>T, p.Arg262Cys Exon 5 10 rs4146960 No change NI
 c.1202+57_61delGTAAA Intron 9 6 No No change No
 c.1731 T>G, p.Asp577Asp Exon 13 1 rs34303676 No change NI
 c.2223+18A>T Intron 17 1 No No change No
UBQLN1 c.1494C>T, p.Ser498Ser Exon 10 5 (and 1 minor  rs2781004 No change No
   homozygote)   
 c.1590C>A, p.Leu530Leu Exon 10 7 (and 1 minor  rs7866234 No change No
   homozygote)   
 c.1617+17G>A Intron 10 8 rs9314722 No change No
1 Out of 16 patients tested 
2  Using splice-prediction programs NNSPLICE version 0.9 by Neural Network (www.fruitfly.org/seq_tools/
splice.html), NetGene 2 Server version 2.42 by CBS Software Package Manager (www.cbs.dtu.dk/services/
NetGene2) and Alex Dong Li’s SpliceSiteFinder (http://violin.genet.sickkids.on.ca/~ali/splicesitefinder.
html)
3 NI = Not investigated     
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DISCUSSION
The analysis reported here represents the largest single-center genome-wide linkage 
search for new susceptibility loci in non-brca1/2 breast cancer families to date. The 
rationale for this study was that there exist further breast cancer genes which confer 
moderate to high risks (6,28). The patterns of familial clustering in the families that 
we selected for our study suggest that such alleles are likely to be dominant. Initial 
suggestive linkage peaks observed in a ‘linkage search’ group of 55 families were sub-
sequently confirmed and confined to a locus on chromosome 9 in a total set of 85 
families. Linkage evidence was most apparent using allele-sharing analyses with the 
Merlin package, with a single point non-parametric lodscore of 4.63 and a multipoint 
score of 3.96 at marker D9S167. These npl scores represent the highest for any single 
locus in a linkage search after the identification of brca1 and brca2, but they are dif-
TABLE 4
Results of array-CGH analysis for 13 BACs in the region 9q21-q22
                                           9q-linked tumors1         9q-nonlinked tumors2 
BAC Mb gene gain loss inc gain loss inc
RP11-66D1 83 TLE1 5% 14% 81% 13% 23% 64%
RP11-432M2 84  9% 0% 91% 26% 3% 72%
RP11-541F16 84,7 RASEF 5% 10% 86% 0% 5% 95%
RP11-439A18 85,3 UBQLN1/HNRPK 32% 7% 62% 13% 13% 74%
RP11-59M22 86,3  18% 0% 82% 23% 5% 72%
RP11-172F7 87,1  64% 23% 13% 59% 18% 23%
RP11-280P22 87,9  41% 7% 52% 31% 5% 64%
RP11-276H19 88,8 GAS1 0% 55% 45% 8% 31% 62%
RP11-423O13 88,9  0% 18% 82% 0% 8% 92%
RP11-40C6 89,3  9% 10% 81% 15% 13% 72%
RP11-249H20 89,4 DAPK1 9% 15% 76% 13% 3% 85%
RP11-65B23 89,6 CCRK 18% 17% 65% 26% 10% 64%
RP11-8B23 91,7 GADD45 5% 29% 67% 0% 28% 72
1  Group of 22 breast tumors from 10 families in which all genotyped patients shared a haplotype around 
D9S167;        
2  Group of 39 breast tumors from 17 families without sharing of a haplotype around D9S167. 
gain, ratio tumor/normal > 0.2 on a 2log-scale; loss, ratio tumor/normal less than –0.2 on a 2log-scale; 
inc, inconclusive (ratios between –0.2 and 0.2)
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ficult to compare with previous studies because these have mainly analysed marker 
data with the more conservative genehunter software. Under a parametric domi-
nant model, however, the hlod at D9S167 was 0.56 (α=0.18), indicating that even 
though the allele-sharing at D9S167 was significant in the total set of families, most 
families did not support linkage to this locus. Indeed, we noted complete allele-
sharing among patients among 25 of the 85 families (29%) at D9S167, and suggestive 
incomplete sharing in 12 other families (14%). We observed extensive haplotype 
 heterogeneity around shared alleles at D9S167. One explanation for this is that there 
is a gene (or genes) near D9S167 in which multiple rare variants confer substantially 
increased risks to breast cancer. The low hlod score at this marker is probably due to 
the small number of families demonstrating complete haplotype sharing among the 
patients in conjunction with the fact that for most families and patients the (founder) 
parents were unavailable for genotyping. In the merlin analysis, the overall informa-
tion content at D9S167 in the 85 families was 42%, which is in agreement with simu-
lation studies with microsatellite maps of ~10 cM and incomplete parental geno-
types.29 Further genotyping of the region at much higher resolutions could therefore 
help to identify regions with more consistent allele-sharing.
Recently the Breast Cancer Linkage Consortium published the results of a genome 
wide linkage search for breast cancer susceptibility genes,1 which included 149 mul-
tiple case non-brca1/2 breast cancer families. The highest lod score under the do-
minant model was 1.80, for a region on chromosome 4. Although several other sug-
gestive lod scores were reported, the number of linkage peaks did not differ from 
the number expected by chance and therefore these peaks probably reflect the play 
of chance rather than true susceptibility loci. In agreement with the bclc-study we 
found no evidence for linkage to markers on 2q32,10 3p26,30 8p12-22,31,32 10q23.32-
q25.3,11 11q23,30 13q2133 and 22q13.1,30,34 which were all previously suggested to har-
bour susceptibility loci. But we also did not find any evidence for linkage on the re-
gions reported by the bclc-publication. The inability to detect strong linkage signals 
may be a reflection of extensive locus heterogeneity. 
The bclc analysis1 included 22 Dutch families that were also part of the 55 families 
investigated here. The npl score near the D9S167 locus in that study was 0.74, and 
although this was the second highest score for the Dutch families, there was no evi-
dence for allele-sharing at this locus in the other 127 families collected in that study, 
derived from Australia, United Kingdom, USA, Canada and France. Of the 22 Dutch 
families, 10 showed allele-sharing at D9S167, but 2 of these on different haplotypes. 
It is possible that our linkage study might have achieved greater statistical power 
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because the families derive from a more homogeneous population (i.e., with reduced 
genetic heterogeneity). The Dutch population exhibits distinct founder mutations 
for several known cancer susceptibility genes,12,14,35,36 and therefore could be conside-
red, to an extent, to be genetically distinct.37 Although a strong founder effect at the 
9q-locus seems less likely, given the diversity of shared haplotypes, such an effect has 
also been observed at brca1 in the presence of extensive allelic heterogeneity.12,13
In a genome-wide scan for linkage in 14 Finnish breast cancer families,10 the second 
highest hlod peak was found at D9S283, just 5 cM distal of D9S167. D9S167 was 
also shown to be linked (with a multipoint parametric lod score of 3.02) to ocular 
melanoma in three Danish families38 with multiple cases of ocular malignant mela-
noma, cutaneous malignant melanoma and other malignancies, including breast 
cancer. In addition, D9S167 was in the center of a small chromosomal deletion in a 
case of acute myeloid leukemia.39 These results suggest there is a gene in this region 
that can be linked to cancer susceptibility. Further evidence that the 9q21 region 
may be involved in a subset of the familial form of breast cancer comes from our 
observation that over 50% of brcax tumors putatively linked to 9q21 show copy-
number loss at this locus, as opposed to 5-25% in sporadic breast tumors.40,41 Others 
did not observe excess copy-number losses of 9q in familial non-brca1/2 breast tu-
mors using classical cgh,33,42 although these patients were selected under different 
criteria than our cases. We previously reported43 that ~30% of the same set of brcax 
tumors showed loss of heterozygosity (or allelic imbalance) at a marker for 9q34, 
which is not significantly higher than found in sporadic tumors.44 Because that 
 marker is a long distance away from D9S167, it is possible that some of the copy-
number losses in the brcax tumors are tightly localized around 9q21.
The number of genes between D9S1843 and D9S283 presently annotated is 49. We 
performed sequence analysis of 5 of these to search for possible susceptibility alleles. 
No clear pathogenic changes were found in any of them. For all genes an apparent 
link with tumorigenesis could be made, such as a Ras GTPase motif in the rasef-
gene (closest to D9S167), transcription regulation (tle1),  or involvement in apop-
tosis (dapk1) or stress response (gadd45γ).45-47 However, a direct link with breast 
cancer has not yet been established for most of these candidates. In sporadic breast 
cancer, the expression of rasef at mrna-level is apparently not reduced.38 Tle1 has 
been suggested to play a role during epithelial differentiation48 and tumor progres-
sion through inhibition of the Wnt–ctnnb1 signaling pathway.45 dapk1 and gad-
d45g are frequently targeted by inactivation through promotor hypermethylation in 
leukemias, lymphomas and a number of epithelial cancers.47,49
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In conclusion, through linkage analysis we have identified a region on 9q21 which 
shows significant haplotype sharing among patients belonging to non-brca1/2 fa-
milies with at least three cases of breast cancer diagnosed before age 60. However, we 
observed extensive haplotype diversity at the shared locus, but have not yet identi-
fied sequence variants in candidate genes that could explain these results. There was 
some suggestion that the somatic genetic changes at this locus differ from that seen 
in sporadic breast tumors, which will have to be confirmed in larger series.
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